- Home
- Software Solutions
- Resources
- Corporate
A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Sponsors:
| Phases:
| |
| Indications | Acronym: | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 25 | |
Additional information about NCT01108458.